The Technical Analyst
Lucid Diagnostics Inc. [LUCD]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Lucid Diagnostics Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-5.63% $0.682
America/New_York / 24 apr 2024 @ 15:38
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 32.92 mill |
| EPS: | -1.260 |
| P/E: | -0.540 |
| Earnings Date: | Mar 26, 2024 |
| SharesOutstanding: | 48.24 mill |
| Avg Daily Volume: | 0.168 mill |
| RATING 2024-04-23 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | |||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.540 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.540 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.597 - 0.769 ( +/- 12.60%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-22 | White Debra | Buy | 150 000 | Employee stock option (right to buy) |
| 2024-02-22 | Sparks Ronald M | Buy | 150 000 | Employee stock option (right to buy) |
| 2024-02-22 | Lapidus Stanley | Buy | 150 000 | Employee stock option (right to buy) |
| 2024-02-22 | Cox James L | Buy | 150 000 | Employee stock option (right to buy) |
| 2024-02-22 | Sokolov Jacque J | Buy | 150 000 | Employee stock option (right to buy) |
| INSIDER POWER |
|---|
| 33.60 |
| Last 57 transactions |
| Buy: 13 183 319 | Sell: 4 158 892 |
Forecast:
16:00 - $0.683
Live Trading Signals (every 1 min)
Forecast
1: 15:47 - $0.683
Forecast 2: 16:00 - $0.683
Forecast 3: 16:00 - $0.683
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.682 (-5.63% ) |
| Volume | 0.210 mill |
| Avg. Vol. | 0.168 mill |
| % of Avg. Vol | 125.38 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For LUCD
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
LUCD
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Latest Press Releases
2024-03-25 17:30:00 - Press Release
Lucid Diagnostics Provides Business Update And Preliminary Fourth Quarter And Full Year 2023 Financial Results
Quarterly esoguard® revenue increased 33 percent sequentially expanding esoguard clinical validity and clinical utility data poised to drive medical policy coverage, including line of sight to medicare coverage conference call and webcast to be held tomorrow, march 26 th at 8:30 am et new york , march 25, 2024 /prnewswire/ -- lucid diagnostics inc. (nasdaq: lucd) ("lucid" or the "company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of pavmed inc. (nasdaq: pavm, pavmz) ( "pavmed"), today provided a business update for the company and presented financial results for the year ended december 31, 2023. conference call and webcast the webcast will take place on march 26, 2024, at 8:30 am, and be accessible in the investor relations section of the company's website at luciddx...
2024-03-21 09:30:00 - Press Release
Lucid Diagnostics Announces Positive Data From The First Prospective Clinical Validation Study Of Esoguard® Esophageal Precancer Testing In A Screening Population
Prospective va screening study demonstrates excellent esoguard sensitivity of 92.9% and negative predictive value of 98.6% compared to upper gastrointestinal endoscopy authors conclude that esoguard is a "powerful screening tool" for esophageal precancer and cancer new york , march 21, 2024 /prnewswire/ -- lucid diagnostics inc. (nasdaq: lucd) ("lucid" or the "company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of pavmed inc. (nasdaq: pavm, pavmz) ( "pavmed"), today announced that investigators at the louis stokes cleveland veterans affairs medical center, led by katarina b. greer, m.d.
2024-03-20 08:30:00 - Press Release
Lucid Diagnostics Announces Multiple Presentations At The Upcoming Digestive Disease Week (ddw) 2024 Conference
Lucid and collaborators will present data on three studies on esoguard® esophageal precancer testing and one on a new genetic classifier of esophageal neoplasia new york , march 20, 2024 /prnewswire/ -- lucid diagnostics inc. (nasdaq: lucd) ("lucid" or the "company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of pavmed inc. (nasdaq: pavm, pavmz) ( "pavmed"), today announced that four abstracts related to its groundbreaking technologies, including its esoguard® esophageal dna test, have been accepted for presentation by it and its collaborators at this year's digestive disease week (ddw) annual meeting 2024—the world's premier meeting for digestive disease professionals...
2024-03-12 08:30:00 - Press Release
Lucid Diagnostics To Hold A Business Update Conference Call And Webcast On March 26, 2024
Conference call and webcast at 8:30am eastern time new york , march 12, 2024 /prnewswire/ -- lucid diagnostics inc. (nasdaq: lucd) ("lucid" or the "company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of pavmed inc. (nasdaq: pavm, pavmz), today announced that it will host a business update conference call and webcast on tuesday, march 26, 2024, at 8:30 am et. during the call, lishan aklog, m.d.
2024-02-16 17:00:00 - Press Release
Lucid Diagnostics Provides Update Regarding World Trade Center Health Program
New york, feb. 16, 2024 /prnewswire/ -- lucid diagnostics inc. (nasdaq: lucd) ("lucid" or the "company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of pavmed inc. (nasdaq: pavm, pavmz) ( "pavmed"), today announced that it was notified by the world trade center health program ("wtchp") that, due to a clerical error, the esoguard® esophageal dna test was incorrectly listed as a covered benefit. wtchp advised lucid on the further steps required, including engaging directly with its clinical centers of excellence.
Latest News
2024-04-19 06:00:00 - InvestorPlace
3 Penny Stocks That Could Make a Big Comeback by the End of Q2
Let's just get something straight off the bat – penny stocks to rebound are risky. They're incredibly treacherous in terms of both short-term downside and longer-term damage to your portfolio.
2023-11-14 22:54:09 - Seeking Alpha
Lucid Diagnostics Inc. (LUCD) Q3 2023 Earnings Call Transcript
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q3 2023 Results Conference Call November 14, 2023 8:30 AM ET Company Participants Michael Parks - VP, IR Dr. Lishan Aklog - Chairman, CEO Dennis McGrath - EVP, CFO Conference Call Participants Kyle Mikson - Canaccord Ross Osborn - Cantor Fitzgerald Mike Matson - Needham & Co Ed Woo - Ascendiant Capital Operator Good morning, and welcome to the Lucid Diagnostics Third Quarter 2023 Business Update Conference Call. All participants will be in a listen-only mode.
2023-11-02 09:18:00 - PRNewsWire
Lucid Diagnostics to Present at Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum
Lishan Aklog, M.D., Chairman & CEO, to Present November 16, 2023, in New York NEW YORK , Nov. 2, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced its Chairman and Chief Executive Officer, Dr. Lishan Aklog, will present at the Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum on November 16, 2023 at 10:00am EST in New York City.
2023-08-15 12:38:03 - Seeking Alpha
Lucid Diagnostics Inc. (LUCD) Q2 2023 Earnings Call Transcript
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q2 2023 Results Conference Call August 15, 2023 8:30 AM ET Company Participants Michael Parks - VP, IR Lishan Aklog - Chairman, CEO Dennis McGrath - EVP, CFO Conference Call Participants Ed Woo - Ascendiant Capital Kyle Mikson - Canaccord Mark Massaro - BTIG Mike Matson - Needham & Co. Operator Good day, and welcome to the Lucid Diagnostics Second Quarter 2023 Business Update Conference Call. [Operator Instructions] Please note, this event is being recorded.
2023-05-16 19:39:08 - Seeking Alpha
Lucid Diagnostics Inc. (LUCD) Q1 2023 Earnings Call Transcript
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q1 2023 Results Conference Call May 16, 2023 8:30 AM ET Company Participants Michael Parks - VP, IR Dr. Lishan Aklog - Chairman and CEO Dennis McGrath - CFO Conference Call Participants Alex Vukasin - Canaccord Genuity Mike Matson - Needham Edward Woo - Ascendiant Capital Operator Welcome to the Lucid Diagnostics Business Update and First Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
2023-04-17 21:45:00 - PRNewsWire
Lucid Diagnostics to Present at 22nd Annual Needham Virtual Healthcare Conference
NEW YORK, April 17, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced that Dr. Lishan Aklog, Chairman and Chief Executive Officer; and Dennis McGrath, Chief Financial Officer will present at the 22nd Annual Needham Healthcare Conference on Thursday, April 20, 2023 at 11:00 AM ET.
2023-03-28 16:41:27 - CNBC
Lucid to cut 1,300 workers amid signs of flagging demand for its EVs
Lucid CEO Peter Rawlinson said the job cuts will hit "nearly every organization and level, including executives."
2023-03-14 14:18:15 - Seeking Alpha
Lucid Diagnostics Inc. (LUCD) Q4 2022 Earnings Call Transcript
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q4 2022 Earnings Conference Call March 14, 2023 8:30 AM ET Company Participants Michael Parks - Vice President, Investor Relations Dr. Lishan Aklog - Chairman and CEO Dennis McGrath - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Ross Osborn - Cantor Fitzgerald Mike Matson - Needham & Co. Mark Massaro - BTIG Edward Woo - Ascendiant Capital Operator Welcome to the Lucid Diagnostics Business Update and Fourth Quarter 2022 Financial Results Conference Call. At this time, all participants will be in a listen-only mode.
2022-11-14 21:50:06 - Seeking Alpha
Lucid Diagnostics Inc. (LUCD) Q3 2022 Earnings Call Transcript
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Adrian Miller - Vice President-Investor Relations Lishan Aklog - Chairman & Chief Executive Officer Dennis McGrath - Chief Financial Officer Conference Call Participants Mike Matson - Needham & Company Ross Osborn - Cantor Fitzgerald Ed Woo - Ascendiant Capital Greetings, and welcome to Lucid Diagnostics Third Quarterly Update Conference Call and Webcast. At this time, all participants are in a listen-only mode.
2022-11-02 08:25:00 - Business Wire
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2022
NEW YORK--(BUSINESS WIRE)-- #CheckYourFoodTube--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that the Company will host a business update conference call and webcast on Monday, November 14, 2022, at 4:30 PM EDT.